In contrast to this observation, it has been reported that mice that received anti-TNF added to combined CTLA-4 and PD-1-blockade had a higher rate of tumor control and survival than mice that were treated with CTLA-4- and PD-1-blockade only [36]. This evidence concerns the gene RPL17 and neoplasm.